Dear Reader,

I hope that you are well.

In this issue of V·Pulse, we are pleased to share with you the clinical opinions on management of juvenile idiopathic arthritis (JIA), particularly during the transition from pediatric to adult rheumatology care. You can also find highlights on managing refractory/relapsed multiple myeloma (RRMM) with immunomodulatory drugs as well as local recommendations on COVID-19 vaccination for adult patients autoimmune rheumatologic diseases.

Please register to subscribe V·Pulse for free at https://www.vpulsehk.com and discover more exciting medical information.
Best wishes,
Dr Roy Yuen-chi Lau
PhD, DBA, FRSPH, MRSC, MSB, CBiol, CSci
Editor-in-Chief
Visit & Sign Up Now
Recognition and Treatment of Patients with Juvenile Idiopathic Arthritis

Dr. Patrick Chong Chun Yin
Specialist in Paediatric Immunology,
Allergy and Infectious Diseases

 
Unmet Needs in Relapsed and Refractory Multiple Myeloma

Prof. Xavier Leleu
Head, Myeloma Clinic,
Head, Department of Haematology, Hôpital La Mileterie, PRC, CHU, Poitiers, France
Combating Relapsed and Refractory Multiple Myeloma in Local Clinical Setting

Dr. Gloria YY Hwang
Associate Consultant,
Honorary Clinical Assistant Professor,
Department of Medicine,
Queen Mary Hospital,
University of Hong Kong
 
If you have any questions, please feel free to contact our Digital Team by email info@vpulsehk.com or by phone at +852 2741 6265.